Restoration of altered MicroRNA expression in the ischemic heart with resveratrol

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Mukhopadhyay, Partha ^a   Mukherjee, Subhendu ^c   Ahsan, Kaimul ^c   Bagchi, Angshuman ^b   Pacher, Pal ^a   Das, Dipak K ^c  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METAL ION; MICRORNA; MICRORNA 21; POTASSIUM ION; RESVERATROL; SODIUM ION; CARDIOTONIC AGENT; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MALE; METAL BINDING; NONHUMAN; OUTCOME ASSESSMENT; RAT; REPERFUSION INJURY; TREATMENT DURATION; ANIMAL; BIOLOGY; COMPUTER PROGRAM; DRUG EFFECT; GENETICS; HEART; METABOLISM; METHODOLOGY; MOUSE; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT;

MUS; RATTUS;

ANIMALS; CARDIOTONIC AGENTS; COMPUTATIONAL BIOLOGY; HEART; MALE; MICE; MICRORNAS; MYOCARDIAL ISCHEMIA; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOFTWARE; STILBENES;

EID: 78650840268     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015705     Document Type: Article

References (38)

1. Bhat KP, Pezzuto JM (2002) Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci 957: 210-229.
2. Das DK, Mukherjee S, Ray D (2010) Resveratrol and red wine, healthy heart and longevity. Heart Fail Rev.
3. Bertelli AA, Das DK (2009) Grapes, wines, resveratrol, and heart health. J Cardiovasc Pharmacol 54: 468-476.
4. Mukherjee S, Lekli I, Gurusamy N, Bertelli AA, Das DK (2009) Expression of the longevity proteins by both red and white wines and their cardioprotective components, resveratrol, tyrosol, and hydroxytyrosol. Free Radic Biol Med 46: 573-578.
5. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, et al. (2006) Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 1091: 151-169.
6. Ungvari Z, Labinskyy N, Mukhopadhyay P, Pinto JT, Bagi Z, et al. (2009) Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol 297: H1876-1881.
7. Imamura G, Bertelli AA, Bertelli A, Otani H, Maulik N, et al. (2002) Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice. Am J Physiol Heart Circ Physiol 282: H1996-2003.
8. Das DK, Maulik N (2004) Conversion of death signal into survival signal by redox signaling. Biochemistry (Mosc) 69: 10-17.
9. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
10. Fabian MR, Sonenberg N, Filipowicz W (2010) Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79: 351-379.
11. Dai R, Phillips RA, Zhang Y, Khan D, Crasta O, et al. (2008) Suppression of LPS-induced Interferon-gamma and nitric oxide in splenic lymphocytes by select estrogen-regulated microRNAs: a novel mechanism of immune modulation. Blood 112: 4591-4597.
12. Bauersachs J (2010) Regulation of myocardial fibrosis by microRNAs. J Cardiovasc Pharmacol.
13. Jiang X, Tsitsiou E, Herrick SE, Lindsay MA (2010) MicroRNAs and the regulation of fibrosis. FEBS J 277: 2015-2021.
14. Ferracin M, Veronese A, Negrini M (2010) Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn 10: 297-308.
15. Nana-Sinkam P, Croce CM (2010) MicroRNAs in diagnosis and prognosis in cancer: what does the future hold? Pharmacogenomics 11: 667-669.
16. Qurashi A, Jin P (2010) Small RNA-mediated gene regulation in neurodevelopmental disorders. Curr Psychiatry Rep 12: 154-161.
17. Kartha RV, Subramanian S (2010) MicroRNAs in cardiovascular diseases: biology and potential clinical applications. J Cardiovasc Transl Res 3: 256-270.
18. Barringhaus KG, Zamore PD (2009) MicroRNAs: regulating a change of heart. Circulation 119: 2217-2224.
19. Suarez Y, Sessa WC (2009) MicroRNAs as novel regulators of angiogenesis. Circ Res 104: 442-454.
20. Divakaran V, Mann DL (2008) The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res 103: 1072-1083.
21. Catalucci D, Latronico MV, Condorelli G (2008) MicroRNAs control gene expression: importance for cardiac development and pathophysiology. Ann N Y Acad Sci 1123: 20-29.
22. Gurusamy N, Lekli I, Mukherjee S, Ray D, Ahsan MK, et al. (2010) Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway. Cardiovasc Res 86: 103-112.
23. Mukherjee S LI, Das DK. Hormetic response of resveratrol against cardioprotection. J Exp Clin Cardiology In Press).
24. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, et al. (2008) MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456: 980-984.
25. Das S, Tosaki A, Bagchi D, Maulik N, Das DK (2006) Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling. J Pharmacol Exp Ther 317: 980-988.
26. Cascio S, D'Andrea A, Ferla R, Surmacz E, Gulotta E, et al. (2010) miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol 224: 242-249.
27. Guttilla IK, White BA (2009) Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 284: 23204-23216.
28. Saunders LR, Sharma AD, Tawney J, Nakagawa M, Okita K, et al. (2010) miRNAs regulate SIRT1 expression during mouse embryonic stem cell differentiation and in adult mouse tissues. Aging (Albany NY).
29. Lu Y, Zhang Y, Shan H, Pan Z, Li X, et al. (2009) MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischaemic cardioprotection. Cardiovasc Res 84: 434-441.
30. Tili E, Michaille JJ, Alder H, Volinia S, Delmas D, et al. (2010) Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFbeta signaling pathway in SW480 cells. Biochem Pharmacol 80: 2057-2065.
31. Tili E, Michaille JJ, Adair B, Alder H, Limagne E, et al. (2010) Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis 31: 1561-1566.
32. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, et al. (2004) Stressdependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303: 2011-2015.
33. Baxter RA (2008) Anti-aging properties of resveratrol: review and report of a potent new antioxidant skin care formulation. J Cosmet Dermatol 7: 2-7.
34. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, et al. (2010) SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1. Journal of Biological Chemistry 285: 8340-8351.
35. Hattori R, Otani H, Maulik N, Das DK (2002) Pharmacological preconditioning with resveratrol: role of nitric oxide. Am J Physiol Heart Circ Physiol 282: H1988-1995.
36. Mukherji S RD, Lekli I, Bak I, Tosaki A, Das DK (2010) Effects of longevinex on cardioprotection: its mechanism of action. Can J Pharmacol Physiol In Press.
37. Mukhopadhyay P, Rajesh M, Batkai S, Kashiwaya Y, Hasko G, et al. (2009) Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol 296: H1466-1483.
38. Chen Y, Gelfond JA, McManus LM, Shireman PK (2009) Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis. BMC Genomics 10: 407.